Universitätsklinikum Schleswig-Holstein (UKSH)

Stromal markers AKR1C1 and AKR1C2 are prognostic factors in primary human breast cancer (2016) Wenners A, Hartmann F, Jochens A, Roemer AM, Alkatout I, Klapper W, Van Mackelenbergh M, et al. Journal article Hartgewebeaugmentationen: Materialwahl (2016) Schlegel KA, Wiltfang J, Lutz R, Schmitt C, Möst T Journal article Impact of Histopathological Factors, Patient History and Therapeutic Variables on Recurrence-free Survival after Ductal Carcinoma in Situ: 8-Year Follow-up and Questionnaire Survey (2016) Van Mackelenbergh MT, Lindner CM, Heilmann T, Alkatout I, Elessawy M, Mundhenke C, Maass N, Schem C Journal article, Review article DISEASE PROGRESSION IN 282 PATIENTS WITH UNDIFFERENTIATED SSC - DATA FROM THE GERMAN NETWORK FOR SYSTEMIC SCLERODERMA (2016) Moinzadeh P, Blank N, Siegert E, Henes J, Susok L, Distler J, Juche A, et al. Conference contribution Targeted Intraoperative Radiation Therapy Tumor Bed Boost During Breast-Conserving Surgery After Neoadjuvant Chemotherapy in TNBC and HER2 Positive Breast Cancer (2016) Kolberg HC, Loevey G, Akpolat-Basci L, Stephanou M, Fasching P, Untch M, Liedtke C, et al. Conference contribution Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial (2016) Janning M, Mueller , Vettorazzi E, Cubas-Cordova M, Gensch , Ben Batalla , Eulenburg ZC, et al. Conference contribution Tumor-infiltrating lymphocytes and response prediction to neoadjuvant chemotherapy in HER2-positive breast cancer (2016) Heppner BI, Untch M, Denkert C, Pfitzner BM, Lederer B, Schmidt W, Eidtmann H, et al. Conference contribution Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP) (2016) Hassel J, Forschner A, Bluhm L, Heinzerling L, Zimmer L, Utikal J, Kaehler K, et al. Conference contribution Oral cavity carcinomas as primary manifestation of telomere maintenance disorders (telomeropathies) (2016) Beier F, Schmitt K, Bouillon AS, Hasenbank C, Vankann L, Ambrosch P, Hoffmann T, et al. Conference contribution Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple negative or luminal B/HER2 normal breast cancer (GENEVIEVE) (2016) Paepke S, Huober J, Sherko K, Eidtmann H, Untch M, Costa SD, Blohmer JU, et al. Conference contribution